CTLA4 and neoplasm: Tumors with dMMR have a high tumor mutational burden, tumor infiltrating lymphocyte enrichment in the microenvironment, and high expression of immunological checkpoint proteins such as PD-1, PD-L1, and CTLA-4 (35).